In the stock market today there have been several opportunities to buy back cheaper due to the recent market selloffs and declines including 70% drops in different stocks over the last year. In my opinion, one of the upcoming opportunities for positive future returns and a potential “multi-bagger” is a stock under the name “Dare Bioscience, Inc.” The stock currently trades under the ticker DARE. One of the benefits of this stock is that it now has a FDA approved drug called Xaciato. Also known as clindamycin phosphate, it is in gel form and is used to treat cases of bacterial vaginosis in women. It is now officially available for purchase, and has been shown to be superior to other treatments pending the circumstance. The stock is currently trading at $1.36 per share, and has been much higher in the past.
Unlike other small pharmaceutical stocks that are a one and done hit, what separates DARE from the masses is that it is currently developing a pipeline of multiple treatments and products. Let’s review some of the current treatments and products being developed:
- Ovaprene – Hormone free monthly contraceptive.
- Sildenafil Cream – For female sexual arousal disorder
- DARE-HRT1 – Hormone therapy
- DARE-VVA1 – Treatment for vulvar and vaginal atrophy
- DARE-FRT1/PTB1 – For pregnancy maintenance
- ADARE 204/214 – Long acting injectable contraception
- DARE-LARC1 – Long acting reversible contraceptive system
- DARE-GML – – Antimicrobial
- DARE-LBT
- Dare-RH1 – male or female contraceptive
(the above were summarized from the Dare Bioscience website)
As you can see, that is quite a pipeline for a stock at $1.36/share as of today. This is in no means investment advice, but I suspect long-term this stock may be much higher as the company continues to grow. The company has various partnerships in the works as well including Organon and Bayer. I am quite impressed with their leadership and am looking forward to following their success in the future.
TannerMD